ArticleThe Journal of biological chemistry2014
Small molecule-directed immunotherapy against recurrent infection by Mycobacterium tuberculosis.
Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Helper T cell bias following tuberculosis chemotherapy identifies opportunities for therapeutic vaccination to prevent relapse.NPJ vaccines · 2023Article
- Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.PLoS pathogens · 2021Article
- Intranasal immunization with peptide-based immunogenic complex enhances BCG vaccine efficacy in a murine model of tuberculosis.JCI insight · 2021Article
- Immunotherapy With 5, 15-DPP Mediates Macrophage M1 Polarization and Modulates SubsequentFrontiers in immunology · 2021Article
- Clofazimine enhances the efficacy of BCG revaccination via stem cell-like memory T cells.PLoS pathogens · 2020Article
- Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection.Frontiers in immunology · 2020Review
- Curcumin Nanoparticles Enhance Mycobacterium bovis BCG Vaccine Efficacy by Modulating Host Immune Responses.Infection and immunity · 2019Article
- The phytochemical bergenin as an adjunct immunotherapy for tuberculosis in mice.The Journal of biological chemistry · 2019Article
- Efficacy of T Regulatory Cells, Th17 Cells and the Associated Markers in Monitoring Tuberculosis Treatment Response.Frontiers in immunology · 2018Article
- Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort.International journal of molecular sciences · 2017Article
- The Human Microbiome in the Fight Against Tuberculosis.The American journal of tropical medicine and hygiene · 2017Review
- The Phytochemical Bergenin Enhances T Helper 1 Responses and Anti-Mycobacterial Immunity by Activating the MAP Kinase Pathway in Macrophages.Frontiers in cellular and infection microbiology · 2017Article
- Nanoparticle-Formulated Curcumin Prevents Posttherapeutic Disease Reactivation and Reinfection withFrontiers in immunology · 2017Article
- Cellular Architecture of Spinal Granulomas and the Immunological Response in Tuberculosis Patients Coinfected with HIV.Frontiers in immunology · 2017Article
- Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity.Frontiers in immunology · 2017Review
- Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.Oncotarget · 2016Article
- Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors.JCI insight · 2016Article
- Mycobacterium tuberculosis TlyA Protein Negatively Regulates T Helper (Th) 1 and Th17 Differentiation and Promotes Tuberculosis Pathogenesis.The Journal of biological chemistry · 2015Article
- Regulatory T-Cells at the Interface between Human Host and Pathogens in Infectious Diseases and Vaccination.Frontiers in immunology · 2015Review
- Simultaneous inhibition of T helper 2 and T regulatory cell differentiation by small molecules enhances Bacillus Calmette-Guerin vaccine efficacy against tuberculosis.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Tuberculosis remains the biggest infectious threat to humanity with one-third of the population infected and 1.4 million deaths and 8.7 million new cases annually. Current tuberculosis therapy is lengthy and consists of multiple antimicrobials, which causes poor compliance and high treatment dropout, resulting in the development of drug-resistant variants of tuberculosis. Therefore, alternate methods to treat tuberculosis are urgently needed. Mycobacterium tuberculosis evades host immune responses by inducing T helper (Th)2 and regulatory T (Treg) cell responses, which diminish protective Th1 responses. Here, we show that animals (Stat-6(-/-)CD4-TGFβRIIDN mice) that are unable to generate both Th2 cells and Tregs are highly resistant to M. tuberculosis infection. Furthermore, simultaneous inhibition of these two subsets of Th cells by therapeutic compounds dramatically reduced bacterial burden in different organs. This treatment was associated with the generation of protective Th1 immune responses. As these therapeutic agents are not directed to the harbored organisms, they should avoid the risk of promoting the development of drug-resistant M. tuberculosis variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.